Effective February 4, 2019, Wisconsin Diagnostic Laboratories (WDL) will transition to a new test method for thyroglobulin and thyroglobulin antibodies.

- The new test measures the same tumor markers. However, results of the current and new tests are not interchangeable.

**Rebaselining/Parallel testing:** Patients whose thyroglobulin and thyroglobulin antibodies levels are routinely monitored will undergo a “re-baselining” process within a six month period. During this time, both the current and new tests will be performed, in parallel, on the same specimen.

- The rebaselining period will begin February 4, 2019 and continue through August 5, 2019.
- Test ordering will remain the same.
- Results obtained using the current test will be reported with results from the new test appended as a comment.
- Parallel testing will be performed at no cost to the patient.
- Providers are encouraged to test patients currently being monitored within the six-month rebaselining period to establish a new baseline.

**Summary:**

<table>
<thead>
<tr>
<th>Test</th>
<th>Mnemonic</th>
<th>Test Code</th>
<th>CPT Code</th>
<th>Current Reference Interval</th>
<th>New Reference Interval</th>
</tr>
</thead>
<tbody>
<tr>
<td>Thyroglobulin</td>
<td>THYROGLOB</td>
<td>4507010</td>
<td>84432</td>
<td>1.6 to 55.0 ng/mL</td>
<td>1.6 to 50.0 ng/mL</td>
</tr>
<tr>
<td>Thyroglobulin Antibodies</td>
<td>THYGLB AB</td>
<td>4500710</td>
<td>86800</td>
<td>&lt;40 IU/mL</td>
<td>&lt;4 IU/mL</td>
</tr>
</tbody>
</table>

For technical questions or additional information, please call:

- Ian Gunsolus, PhD, Associate Director of Clinical Chemistry and Toxicology, 414.805.6972, igunsolus@mcw.edu